Magellan Asset Management Ltd Purchases 36,609 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Magellan Asset Management Ltd grew its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 636,734 shares of the medical equipment provider’s stock after buying an additional 36,609 shares during the quarter. Magellan Asset Management Ltd’s holdings in Zimmer Biomet were worth $57,255,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Key Financial Inc lifted its position in Zimmer Biomet by 164.6% during the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 163 shares during the period. Flagship Harbor Advisors LLC bought a new position in Zimmer Biomet during the fourth quarter valued at approximately $32,000. Grove Bank & Trust lifted its position in Zimmer Biomet by 431.6% during the fourth quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 328 shares during the period. Headlands Technologies LLC bought a new position in Zimmer Biomet during the second quarter valued at approximately $37,000. Finally, Basepoint Wealth LLC bought a new position in Zimmer Biomet during the fourth quarter valued at approximately $38,000. 88.89% of the stock is owned by institutional investors.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the transaction, the senior vice president directly owned 10,224 shares of the company’s stock, valued at $967,803.84. This trade represents a 20.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet Stock Performance

ZBH opened at $86.72 on Friday. The stock has a market capitalization of $16.78 billion, a price-to-earnings ratio of 22.52, a PEG ratio of 1.96 and a beta of 0.47. The company has a fifty day moving average of $87.69 and a 200 day moving average of $90.50. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $108.29. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.23. The company had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. Zimmer Biomet’s quarterly revenue was up 9.3% on a year-over-year basis. During the same period last year, the company posted $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 24.94%.

Analyst Upgrades and Downgrades

ZBH has been the topic of several recent analyst reports. Citizens Jmp decreased their price objective on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research report on Wednesday, April 29th. Leerink Partners initiated coverage on shares of Zimmer Biomet in a research report on Monday, April 13th. They set a “hold” rating and a $101.00 price objective on the stock. Wall Street Zen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Robert W. Baird set a $92.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $102.70.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.